Compare Lockheed Martin Corporation (LMT) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lockheed Martin Corporation vs Medpace Holdings Inc — how do they compare? Lockheed Martin Corporation trades at $508.35 (market cap $117.22B), while Medpace Holdings Inc trades at $620 (market cap $16.82B). The key difference: Lockheed Martin Corporation is far larger — about 7× Medpace Holdings Inc's market cap, and Lockheed Martin Corporation pays a 2.72% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lockheed Martin Corporation for 86 Days and Medpace Holdings Inc for 14 Days on average.
| LMT | MEDP | |
|---|---|---|
Market Cap | $117.22B | $16.82B |
Volume | 1,101,121 | 223,093 |
Sector | Industrials | Health |
52-Week High | $676.70 | $630.19 |
52-Week Low | $439.19 | $393.42 |
Typical Hold Time | 86 Days | 14 Days |
Enterprise Value | $133.96B | $16.44B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lockheed Martin (LMT) trades at $508.18, up 1.79% with a bearish technical signal despite recent earnings beat. The defense contractor shows strong fundamentals with $75.05B revenue, 8.16% net margin, and robust cash flow of $8.56B from operations. Recent news highlights AI integration and F-35 program developments, while analyst consensus remains bullish with a $635.33 price target representing 25% upside potential.
LMT presents a compelling value opportunity with attractive valuation multiples (P/E 18.73, P/S 1.53) and 23-year dividend growth streak. Key risks include dependency on Pentagon contracts and fixed-price contract volatility. The stock's current discount to analyst targets and defensive positioning in aerospace/defense sector support long-term investment case despite near-term technical weakness.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
